Digital therapeutics developer GAIA and Daiichi Sankyo Europe, part of Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568), on Thursday announced an exclusive strategic partnership to commercialise the digital therapeutic lipodia in Europe upon regulatory approval.

This collaboration combines GAIA's expertise in evidence-based digital therapeutics with Daiichi Sankyo Europe's experience in cardiovascular risk management.

Under the agreement, Daiichi Sankyo Europe will obtain exclusive rights to lipodia, initially covering Germany with potential expansion across major European markets. The therapy is designed to support adults with hypercholesterolaemia through clinically validated, non-pharmacological interventions that encourage sustainable behavioural change.

Lipodia is a fully automated digital therapeutic that adapts to individual patient needs through interactive dialogues and behavioural health methods. The platform can be accessed on connected devices, allowing flexible and location-independent use.

GAIA plans to submit lipodia for reimbursement through Germany's DiGA pathway once data from a pivotal phase 3 randomised controlled trial become available. If approved, physicians would be able to prescribe the therapy as part of routine cardiovascular care.